Cargando…

Understanding the pharmacokinetics of Favipiravir: Implications for treatment of influenza and COVID-19

Detalles Bibliográficos
Autores principales:	Ison, Michael G., Scheetz, Marc H.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2021
Materias:	Commentary
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7785424/ https://www.ncbi.nlm.nih.gov/pubmed/33418497 http://dx.doi.org/10.1016/j.ebiom.2020.103204

Ejemplares similares

Population pharmacokinetics of favipiravir in patients with COVID‐19
por: Irie, Kei, et al.
Publicado: (2021)

Favipiravir and the Need for Early Ambulatory Treatment of SARS-CoV-2 Infection (COVID-19)
por: McCullough, Peter A.
Publicado: (2020)

Pharmacokinetics of Favipiravir in Critically Ill Patients With COVID‐19
por: Irie, Kei, et al.
Publicado: (2020)

The mechanism of resistance to favipiravir in influenza
por: Goldhill, Daniel H., et al.
Publicado: (2018)

Role of favipiravir in the treatment of COVID-19
por: Joshi, Shashank, et al.
Publicado: (2021)

Combined treatment of molnupiravir and favipiravir against SARS-CoV-2 infection: One + zero equals two?
por: Eloy, Philippine, et al.
Publicado: (2021)

Favipiravir and the Need for Early Ambulatory Treatment of COVID-19
por: Korman, Tony M.
Publicado: (2021)

Mechanism of action of favipiravir against SARS-CoV-2: Mutagenesis or chain termination?
por: Zhao, Lei, et al.
Publicado: (2021)

Clinical efficacy and safety of favipiravir in the treatment of COVID-19 patients
por: Chen, Ping-Jen, et al.
Publicado: (2021)

Regional trends in the use of steroids and favipiravir for COVID-19 treatment
por: Asai, Yusuke, et al.
Publicado: (2023)

An economical and practical procedure of favipiravir synthesis for the treatment of Covid-19
por: Karatas, Hacer, et al.
Publicado: (2022)

Favipiravir inhibits acetaminophen sulfate formation but minimally affects systemic pharmacokinetics of acetaminophen
por: Zhao, Yanli, et al.
Publicado: (2015)

Favipiravir for COVID-19 in a Patient on Hemodialysis
por: Hirai, Daisuke, et al.
Publicado: (2021)

Use of Favipiravir in Lactating Mother With COVID-19
por: Karabayır, Nalan, et al.
Publicado: (2021)

Hematological Malignancy Patients, COVID-19, and Favipiravir
por: Mungmunpuntipantip, Rujittika, et al.
Publicado: (2021)

Future of antivirals in COVID-19: The case of favipiravir
por: Kow, Chia Siang, et al.
Publicado: (2022)

Evaluation of the effect of favipiravir on patients with COVID-19
por: Kamali, Alireza, et al.
Publicado: (2023)

Favipiravir-resistant influenza A virus shows potential for transmission
por: Goldhill, Daniel H., et al.
Publicado: (2021)

Experimental Treatment with Favipiravir for COVID-19: An Open-Label Control Study()
por: Cai, Qingxian, et al.
Publicado: (2020)

1147. Regional Trends in Favipiravir and Steroid Use in the Treatment of COVID-19
por: Asai, Yusuke, et al.
Publicado: (2022)

Treatment of COVID-19: implications for antimicrobial resistance in Africa
por: Iwu, Chinwe Juliana, et al.
Publicado: (2020)

Mass vaccination campaign during the 2016 influenza outbreak in Panama: Challenges and implications for COVID-19 vaccination efforts
por: Castro, Franz, et al.
Publicado: (2022)

Efficacy of favipiravir in COVID-19 treatment: a multi-center randomized study
por: Dabbous, Hany M., et al.
Publicado: (2021)

The Combined Effect of Oseltamivir and Favipiravir on Influenza A Virus Evolution
por: Ormond, Louise, et al.
Publicado: (2017)

Understanding vaccine hesitancy in COVID-19
por: Trogen, Brit, et al.
Publicado: (2021)

Effect of favipiravir and an anti-inflammatory strategy for COVID-19
por: Yamamura, Hitoshi, et al.
Publicado: (2020)

Favipiravir exposure and pregnancy outcome of COVID-19 patients
por: Tırmıkçıoğlu, Zeynep
Publicado: (2022)

PIONEER trial: favipiravir to treat moderate COVID-19
por: Shalhoub, Sarah
Publicado: (2023)

The Pharmacokinetic and Pharmacodynamic Properties of Hydroxychloroquine and Dose Selection for COVID-19: Putting the Cart Before the Horse
por: Morrisette, Taylor, et al.
Publicado: (2020)

Elevation of Serum Transaminase Levels Due to Favipiravir Use in the Treatment of COVID-19
por: Bayram, Mehmet, et al.
Publicado: (2021)

Drug Fever Due to Favipiravir Administration for the Treatment of a COVID-19 Patient
por: Tawara, Junsuke, et al.
Publicado: (2021)

Acute Psychosis in COVID-19: Is It Due to Favipiravir Treatment or Acute Viral Illness?
por: Duyan, Murat, et al.
Publicado: (2021)

Favipiravir for the treatment of patients with COVID-19: a systematic review and meta-analysis
por: Manabe, Toshie, et al.
Publicado: (2021)

A review of the safety of favipiravir – a potential treatment in the COVID-19 pandemic?
por: Pilkington, Victoria, et al.
Publicado: (2020)

Adverse events associated with nafamostat mesylate and favipiravir treatment in COVID-19 patients
por: Hifumi, Toru, et al.
Publicado: (2020)

Real-World Experience with Favipiravir for the Treatment of Mild-to-Moderate COVID-19 in India
por: Joshi, Shashank, et al.
Publicado: (2022)

Comparing ICU admission rates of mild/moderate COVID-19 patients treated with hydroxychloroquine, favipiravir, and hydroxychloroquine plus favipiravir
por: Guner, Rahmet, et al.
Publicado: (2021)

Phase 2a, open-label, dose-escalating, multi-center pharmacokinetic study of favipiravir (T-705) in combination with oseltamivir in patients with severe influenza
por: Wang, Yeming, et al.
Publicado: (2020)

Clinical efficacy of Nafamostat Mesylate in combination with Favipiravir for COVID-19 pneumonia treatment review article
por: Abduljabbar, Maram H.
Publicado: (2021)

A POPULATION PHARMACOKINETIC MODELING APPROACH TO EVALUATE THE CURRENT DOSING RECOMMENDATIONS OF FAVIPIRAVIR IN EGYPTIAN SUBJECTS
por: Salem, A., et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_k3mb4qoo2035ib1p097guopfrd